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Abstract
Background: Increasing the coverage of community-based treatment of childhood pneumonia (CCM) is part of the
strategy to improve child survival, increase life-expectancy at birth and promote equity in Ethiopia. However, full
coverage of CCM has not been reached in any regions of the country. There are no sub-national cost-effectiveness
analyses available to inform decision makers on the most equitable scale up strategy.
Objectives: Our first objective is to estimate the sub-national cost-effectiveness and the interindividual inequality
impacts of scaling up CCM coverages to 90% in each region. Our second objective is to explore the costs, health
effects, and geographical inequality impacts associated with three scale-up scenarios promoting different policy-
aims: maximizing health, reducing geographical inequalities, and achieving 90% universal coverage.
Methods: We used Markov modelling to estimate the sub-national cost-effectiveness of CCM in each region. All
data were collected through literature review and adjusted to the region-specific proportions of the rural
population. Health effects were modeled as life years gained and under-five deaths averted. Interindividual and
geographical inequality impacts were measured by the GINI index applied to health. In scenario analysis we
explored three different scale-up strategies: 1) maximizing health by prioritizing the regions where the intervention
was the most cost-effective, 2) reducing geographical inequalities by prioritizing the regions with high baseline
under-five mortality rate (U5MR), and 3) universal upscaling to 90% coverage in all the regions.
Results: The regional incremental-cost effectiveness ratio (ICER) of scaling up the intervention coverage varied from
26 USD per life year gained in Addis to 199 USD per life year gained in the Southern Nations, Nationalities, and
Peoples’ region. Universal upscaling of CCM in all regions would cost about 1.3 billion USD and prevent about 90,
000 under-five deaths. This is less than 15,000 USD per life saved and translates to an increase in life expectancy at
birth of 1.6 years across Ethiopia. In scenario analysis, we found that prioritizing regions with high U5MR is effective
in reducing geographical inequalities, although at the cost of fewer lives saved as compared to the health
maximizing strategy.
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Conclusions: Our model results illustrate a trade-off between maximizing health and reducing health inequalities,
two common policy-aims in low-income settings.
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Introduction
Universal health coverage (UHC) is achieved when the
entire population has access to essential medical services
and can access these services without being exposed to
financial hardship [1]. Achieving universal health coverage
is high on the agenda of the 2030 sustainable development
goals and tightly interlinked with all the focus areas on
poverty, inequality and health. However, health resources
are limited and there is an inevitable need to set priorities
when progressing towards universal health coverage.
Policy makers allocating scarce resources need evidence
on expected costs and benefits associated with different
scale-up strategies for essential health interventions.
Ethiopia has achieved considerable improvements in
population health and child survival over the past
decade. However, many preventable deaths are still
occurring, and some regions seem to be left behind in
the progress that has been made. In 2016, the under-five
mortality rate ranged from 39 deaths per 1000 live births
in Addis Ababa to 125 deaths per 1000 live births in
Afar [2]. Pneumonia was among the three major causes
of under-five mortality throughout Ethiopia. Effective
treatment is available, but the coverage remains low.
Scaling up the coverage of community-based treatment
for childhood pneumonia (CCM) through the Health
Extension Program could be an effective strategy to
further reduce the under-five mortality rate (U5MR)
and promote equity.
The Health Extension Program was launched by the
government in 2004 with the aim of increasing coverage
of primary health care services in Ethiopia. The Health
Extension Program consists of local, government salaried
women who do preventive work and provide basic
curative services in their assigned kebele (community).
Two health extension workers are typically stationed at
each local health posts serving a population of 5000
people on average. Integrated community case management
(iCCM) and community-based treatment of pneumonia
(CCM) in children less than 5 years of age were included as
part of the essential services provided by the health exten-
sion workers in 2010. However, only 29.2% of rural children
and 59.1% of urban children with symptoms of pneumonia
sought treatment in 2016 [2].
Despite efforts to reach rural and poor population with
high impact interventions through the Health Extension
Program, evidence suggests that inequalities in important
child health indicators have increased [3]. Distance to the
nearest health facility and to the region of residence are
two important geographical factors that influence both
health service utilization and child health outcomes [4, 5].
In general, poor and rural populations are often deprived
of health compared to rich and urban populations. More-
over, there are currently substantial geographical inequal-
ities in health service coverage, life expectancy at birth
and child health outcomes between the major regions of
Ethiopia [3]. These geographical health inequalities are
avoidable and most often associated with geographical
inequalities in the distribution of other resources, such as
income.
When progressing towards UHC, policy makers need
to consider both the inequality impacts and the cost-
effectiveness of prioritizing different strategies. Previous
studies have already shown that pneumonia treatment is
pro-poor and provides protection from financial risk
[6, 7]. It has been shown previously that scaling up
coverage of pneumonia treatment would be cost-effective
at a national level [6, 8]. However, to our knowledge, no
studies on sub-national cost-effectiveness of pneumonia
treatment have yet been published, nor have previous
studies investigated the impacts of scaling up treatment
coverage on geographical inequalities.
The regions of Ethiopia are diverse in terms of influential
factors such as available infrastructure, wealth, local epi-
demiology, background mortality and baseline coverage of
pneumonia treatment. These factors are likely to affect both
the costs and the expected benefits of providing pneumonia
treatment at the community level, and we believe that data
on regional cost-effectiveness would inform policy planning
more effectively than national averages alone [9]. Our first
aim is to model the sub-national cost-effectiveness and the
inequality impacts of scaling up coverage of community-
based treatment of childhood pneumonia (CCM) in each
region. Our second aim is to explore the costs, health
effects and geographical inequality impacts of three scale-
up strategies promoting different policy aims: decreasing
geographical inequalities in life expectancy and child
survival, maximizing health, and universal scale-up.
Methods
We used Markov modeling in the software program
TreeAge to model health and economic impacts of
scaling up coverage of CCM from baseline to a target
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coverage of 90% in each of Ethiopia’s eleven major re-
gions. Each regional model was populated with 2016
region-specific data on cost per treatment, incidence of
childhood pneumonia, background mortality, and base-
line coverage of the intervention. Untreated case fatality
rate and treatment effect were assumed to be similar in
all the regions. Region-specific inputs are displayed in
Table 1 and fixed model inputs are displayed in Table 2.
We assumed that all treatments were provided to outpa-
tients under universal public coverage.
Markov modeling
Figure 1 provides an overview of our Markov model.
The model has two arms labelled baseline and target
coverage. The branches within the arms represent the
probabilities that individuals within the modeled 2016
birth cohort would progress through the health events
labeled at each branch. The CCM intervention is present
during only the first five cycles. At the end of each cycle,
one proportion of the cohort moves back to the “Alive
and well” status, whereas the other proportion moves to
the “Death” status. Those who returned to the “Death”
status are removed from the model, whereas each return
to the “Alive and well” status is counted as one life year
completed (illustrated by the survival curves in Fig. 2).
We extrapolated results by running the model for a total
of 120 cycles until everyone in the model cohort was
dead. Since the model starts at age zero and runs for
120 cycles, output adds up to life expectancy. Model
inputs were specific for each region, but the structure
of the models did not change.
Model inputs on incidence of pneumonia
Data on prevalence of pneumonia, under-five mortality
rates by all causes and baseline coverage in each region
were collected from the Demographic and Health Survey
2016 (DHS 2016). The DHS 2016 estimated the preva-
lence of pneumonia by asking mothers of children under
5 years of age whether their child had experienced clin-
ical symptoms of pneumonia during the 2 weeks prior to
the interview. Clinical symptoms are defined as cough
accompanied by short, rapid breathing that was chest-
related, and/or difficult breathing that was chest-related
[2]. In this survey, baseline treatment coverage was esti-
mated as the percentage of children with symptoms of
pneumonia who received clinical examinations and oral
antibiotics from a health professional.
We used the following formula to estimate the annual
incidence of pneumonia among children below the age
of five:
Incidence = prevalence/duration of disease [16]
The estimated incidence of pneumonia varied from
0.453 cases per year in the Amhara region to 0.040 cases
per year in the Harari region (Table 2). Our calculations
were comparable to estimates of incidence of childhood
pneumonia in comparable settings [11].
Model inputs on background mortality
Age-specific mortality rates among adults affect the incre-
mental life years gained by reducing U5MRs, and since
U5MR is an acknowledged predictor of general population
health, the large regional inequalities in U5MRs are likely
to be reflected in mortality among older age groups.











Afar 76.7 11.5 247.8 0.244 44 %
Beni-S. 60.2 9.2 271.3 0.102 29 %
Somali 50.5 4.3 271.3 0.119 32 %
Dire Dawa 16.4 1.7 124.8 0.221 50 %
Gambela 60.2 9.2 124.8 0.198 29 %
SNNP 64.9 7.0 288 0.385 43 %
Amhara 57.3 4.1 277.7 0.453 29 %
Oromia 56.6 3.9 281.6 0.419 26.4 %
Harari 52.9 7.8 163.9 0.04 45 % a
Tigray 57.8 5.6 255.1 0.436 34 %
Addis 30.0 5.0 45 0.153 59 %
National 48.5 5.1 262.1 0.397 33 %
Urban 59.1 %
Rural 29.2 %
aInfant mortality is the risk of dying before reaching the age of one
bChild mortality is the yearly risk of dying in the age group 1-5
cCalculated by assuming 4.6 days mean duration of disease [2, 10]
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However, only life tables representing national averages
were available for age-specific mortality rates among
adults and children older than 5 years of age. Therefore,
we modeled adult mortality rates based on the assumption
that the U5MR is associated with mortality among older
age groups of the same population. In practice, we se-
lected Ethiopian abridged life tables from the 2015 UN
world population prospect [17] and matched each region
to a national life table in a time period with a similar
U5MR as the one observed for the region in 2016 [18].
The life table from this time period was used as a proxy
for adult mortality rates in that region.
There are no census data from 2016. Without taking
into account the effect of still births, we used regional
fertility rates and data on the total number of women in
each region to yield a rough estimate of the number of
births in 2016 [2, 19]. We used these estimates as size
variables in the calculations of weighted averages of the
effects observed in each region, the budget impact and
the geographical Gini coefficients.
Model inputs on the effectiveness and unit costs of CCM
Data on effectiveness of the treatment were collected
from a previously published systematic review of studies
Table 2 Fixed model inputs
Model parameters References/assumptions
Untreated case fatality rate (CFR) 0.0351 [11]
Treatment efficacy in reducing CFR 0.70 [12, 13]
Cycles 120 Lifetime analysis
Discounting of costs 0.03 [14]
Discounting of effects 0.03 [14]
Target coverage 0.90 Per WHO definition of UHC
2016 GDP per capita 713 USD [15]
Fig. 1 Markov model
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assessing CCM of pneumonia in developing countries
[12]. The review concluded that CCM on average re-
duces the case fatality rate of pneumonia in children less
than 5 years of age by 70% (Table 2). We applied this as
our input for treatment effects in all the regions.
Data on treatment costs were collected through litera-
ture review. We did not encounter any data on regional
cost per treatment. However, previous studies indicate
that there are significant differences in costs of providing
community health services in different geographical con-
texts [9, 20]. The inputs for costs per treatment in each
region were therefore adjusted for rural and urban
residency.
One study from Kenya showed that it was 7.2 times
more expensive to provide community health services in
rural areas compared to urban areas [9]. We assumed
that rural Ethiopia would observe a similar increase in
cost per treatment compared to urban Ethiopia. We
applied a cost per treatment provided for patients with
urban residency of 45 USD [8, 21], and the cost per
treatment provided for patients with rural residency was
modelled to be 7.2 times more expensive (Table 1).
However, most regions of Ethiopia have both rural and
urban population [22]. The following formula was used
to estimate average costs per treatment in each region:
Average cost per treatment = (45 ∗ x) + (45 ∗ 7.2 ∗ y),where
x is the proportion with urban residency while y is the
proportion with rural residency.
The studies we relied on to estimate the costs per
treatment costed the intervention from a providers’ per-
spective. Cost items classified as personnel costs, capital
costs or supply costs were included. These were further
divided into patient care costs and overhead costs [21].
In our Markov modeling, we did not include initial
training of health personnel or capital costs. Costs were
discounted at a 3% rate.
Estimation of the intervention effects on health and
health inequalities
We modeled effects of scaling up coverage of CCM as
life expectancy gains for children less than 5 years of
age. The children who recovered from pneumonia were
assumed to continue to live with the same health risks
as the overall population. We did not apply disability
weights to the effect measure as we were primary interested
in mortality reduction afforded by the intervention. Hence,
the incremental effects of the intervention represent gains
in life expectancy at birth. We half-cycle corrected and dis-
counted the effects at a 3% rate. The incremental cost-
effectiveness ratios were calculated by dividing incremental
costs by incremental life years gained.
The Gini coefficient is a measure of inequality (here
applied to health), represented by a number between 0
and 1 where 0 represents absolute equality in the distri-
bution of a chosen variable, and 1 represents a situation
in which all of the chosen variable belong to one individ-
ual. Gini coefficients can be used to describe inequalities
in life expectancy between individuals or population
groups [23]. We used the DASP extension of the
STATA software to calculate the Gini coefficients quan-
tifying inequalities in life expectancy between the regions
and between individuals within each region. In our cal-
culations of geographical inequalities, we applied model
results on regional life expectancies at birth as the health
variable, and estimated numbers for children born in
2016 as the size variables. Data from survival curves
Fig. 2 Population survival curves under baseline and universal coverage
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provided by the Markov models were applied as the size
and health variables for calculation of interindividual
health inequalities.
Scale-up scenarios
In the regional scenario analysis, we explored three
possible objectives: health maximization, reducing geo-
graphic inequality, and universal scale-up. The first two
scenarios have lower costs and could be possible path-
ways to universal scale-up. We estimated incremental
costs, reduction in national U5MR, incremental effects,
and interindividual GINI impacts of 1) maximizing
health by scaling up to 90% coverage in the six regions
where the intervention is the most cost-effective, 2)
reducing geographic inequality by scaling up to 90%
coverage in the three regions with the highest under
five mortality rates, and 3) universal scale-up to 90%
coverage in all regions. For all scenarios, we estimated
expected health impacts across Ethiopia by adding the
weighted averages of the effects observed in each region.
Results
In total, scaling up coverage of CCM to 90% in all re-
gions would decrease the Ethiopian U5MR from 67 to
52 deaths per 1000 live births. Figure 3 shows the impact
on U5MR in each region.
Reduced U5MR translates as increased life expectancy.
Scaling-up treatment coverage to 90% in all regions
would increase the average life expectancy at birth from
63.18 to 64.73 years, a 1.55 years gain. At a regional level,
the incremental effects of scaling up the intervention
coverage to 90% varied from 0.13 life years gained in
Harari to 1.93 life years gained in Oromia (Table 3). The
highest incremental effects were observed in regions
with a high incidence of pneumonia and low baseline
coverage of the intervention.
Table 4 shows total annual costs of the intervention at
target and baseline coverage in each region and in total.
Universal scale-up of CCM would cost about 1.3 billion
USD. The incremental costs of scaling up intervention
coverage were highest in regions with a large rural popu-
lation, low baseline coverage of the intervention and
high incidence of pneumonia. The program costs in-
creased further in regions with a large 2016 birth cohort,
such as the SNNP region.
The incremental cost-effectiveness ratio (ICER) of
scaling up coverage ranged from 26.15 USD per life year
gained in Addis to 195.80 USD per life year gained in
SNNP region (Fig. 4).
Increasing the coverage of pneumonia treatment
would decrease U5MR and alter the survival curves,
translating as reduced interindividual inequalities.
Table 5 shows the Gini coefficients for interindividual
Fig. 3 Under five mortality rates in each region at baseline and universal coverage. **. **Geographical GINI and the slope of inequality: The
geographical GINI indexes are determined by the slope of inequality in Fig. 3 (dotted lines) and by the size of the regions. Since the size variable
remains the same before and after scale-up, the geographical GINI index will increase from one scenario to another if the slope of the inequality
increases, as illustrated in the comparison between baseline coverage and universal coverage. Conversely, the GINI index would decrease if the
slope of inequality decreased
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inequalities in life expectancy within each of the 11 re-
gions at baseline and target coverage. Reducing U5MR
by increasing coverage of CCM translates as decreased
interindividual inequalities in all the regions.
Scenario analysis
Table 6 shows the incremental costs, the incremental life
years gained, the decrease in U5MR and the interindividual
and geographical Gini impacts of three possible scenarios:
health maximization, decreasing geographical inequalities,
and universal scale-up. Addis Ababa, Gambela, Dire Dawa,
Harari and Tigaray were the regions in which the interven-
tion was the most cost-effective, and Afar, Beni-Shangul
and Somali were the regions with the highest baseline
under five mortality rates.
Universal scale-up to 90% coverage in all regions
would substantially alter the survival curves and decrease
interindividual inequalities in life expectancy (Table 6).
The health maximizing strategy and the strategy prioritizing
the worse off both yielded slight decreases in interindividual
Gini with much lower incremental costs (Table 6). As
shown in Table 6, only the targeted strategy to increase
treatment coverage in the regions with the highest U5MR
decreased regional inequalities in life expectancy. The other
two strategies, health maximization and universal scale-up,
both increased regional inequalities in life expectancy.
Discussion
According to the final report of the WHO Consultative
Group on Equity and Universal Health Coverage, cost-
effectiveness, priority to the worse off, and financial risk
protection are important concerns for evaluating which
health care interventions should be ranked first in a
universal health care package [24]. They also argue that
efforts should be made to prevent underprivileged sub-
populations from being left behind. Our results indicate
that scaling up coverage of pneumonia treatment would
be cost-effective in all the eleven major regions of
Table 3 Life expectancy at target and baseline coverage






Affar 52.13 52.82 0.69
Amhara 56.42 58.30 1.89
SNPS 56.95 58.19 1.24
Beni-Shangul 57.84 58.27 0.43
Gambela 57.85 58.68 0.83
Somali 57.95 58.41 0.46
Dire Dawa 58.86 59.48 0.62
Oromia 59.76 61.69 1.93
Tigray 61.04 62.84 1.80
Harari 62.74 62.87 0.13
Addis 70.69 71.09 0.40
Table 4 Total and incremental costs (USD)
Total cost at baseline
coverage (USD)




Addis 1,200,000 1,900,000 600,000
Tigaray 32,100,000 86,000,000 54,000,000
Harai 200,000 400,000 200,000
Amhara 138,400,000 434,100,000 295,700,000
Dire Dawa 1,100,000 1,900,000 900,000
Gambela 500,000 1,600,000 1,000,000
Somali 21,000,000 59,000,000 38,200,000
Beni-Shangul 1,800,000 5,600,000 3,900,000
Oromia 273,000,000 943,000,000 669,000,000
SNPS 219,500,000 463,500,000 244,000,000
Affar 12,000,000 24,700,000 12,700,000
SUM 700,800,000 2,022,000,000 1,321,000,000
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Ethiopia, and that the intervention could reduce both
interindividual and geographical inequalities in life ex-
pectancy. Moreover, making targeted efforts to scale-up
the coverage of high priority interventions in underpriv-
ileged regions first would prevent groups of people
disadvantaged by residence from being left behind.
Our results on incremental cost effectiveness ratio of
scaling up pneumonia treatment coverage in the eleven
major regions are comparable to those of published
literature, in which we found incremental cost effective-
ness ratios (ICERs) ranging from 26,6 to 208 USD per
DALY averted [25, 26]. Geographical factors varying
between the different study settings may account for the
large dissimilarities found in previously published cost-
effectiveness analysis. However, few previous studies
have investigated subnational cost-effectiveness of
community case management of pneumonia, nor the im-
pacts of rural residence on costs per treatment.
There are several data limitations and weaknesses in
this study. The first limitation is our estimation of costs
per treatment in rural compared to urban areas. The
study we relied on for these calculations was small and
undertaken in Kenya which has a different strategy for
delivery of community-based services [9]. However, we
assumed that geographically varying factors identified in
the Kenyan study, such as population density and attrition
rates among local health workers, would be comparable to
the Ethiopian context. In 2016, Berman et al. reported the
costs of providing primary health care services as varying
by a factor of more than five between the regions of
Ethiopia [20]. Their results support our estimates of
region-specific costs per treatment.
The second limitation is that we assumed the untreated
case fatality rate of pneumonia was similar across all re-
gions of Ethiopia. This may not be the case. Malnutrition,
coinfection with HIV and low birth weight are some of
the factors that influence the severity of pneumonia infec-
tions in children [27]. The prevalence of these risk factors
varies between regions. Essentially, stronger evidence on
sub-national cost-effectiveness would require more pri-
mary studies on how much geographical and regional
factors influence case fatality rates and other key inputs
for economic analysis.
We based our estimations of yearly incidence of
pneumonia on data from the Demographic and Health
survey 2016 [2]. Some of these estimations are high when
compared to results from other studies [28]. There are
several possible explanations. Firstly, the DHS data could
have been collected during high season of the disease.
Secondly, some of the children identified as having had
pneumonia might have had other medical explanations of
Fig. 4 Incremental cost effectiveness ratio (ICER) in each region
Table 5 Gini coefficients for interindividual inequalities in each
region
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their symptoms, such as common cold. In the survey,
pneumonia was not confirmed as the cause of symptoms
by any biomedical tests.
A third limitation is that we did not include costs of
demand generation, although evidence suggests that
demand side barriers are major causes of sustained low
intervention coverage [29, 30]. To focus on demand gen-
eration would be especially appropriate in Ethiopia where
community health workers have already been deployed
throughout the country but the utilization of key health
services remains low [30]. Strategies such as the health de-
velopment army have been initiated, but to our knowledge
there is yet no evidence available on its associated costs
and effects.
The cost-effectiveness threshold is the upper ICER to
be considered cost-effective within a given health
budget. Investing in health interventions that are above
this threshold would draw resources away from more
cost-effective interventions and would reduce total
population health [31]. If we adopt a cost-effectiveness
threshold of 50% of the GDP per capita, as suggested by
Woods et al., scaling up coverage of CCM to 90% would
be cost effective in all the regions of Ethiopia. However,
even the threshold of 50% of the GDP per capita could
be too high. Woods et al. indicate that a cost-effectiveness
threshold between 4 and 51% of GDP per capita could be
more appropriate for low to middle income countries,
such as Ethiopia [31].
Concerns about reducing inequalities may justify giv-
ing priority to investment in regions where the health in-
terventions are proven less cost-effective than in other
regions where the interventions are more cost-effective
[24]. This trade-off depends on the decision makers’
level of aversion to inequality [32]. All the scale-up strat-
egies we explored reduced interindividual inequality at a
regional and national level. However, only the strategy
prioritizing the worst-off regions reduced geographical
inequalities. Since there are considerable inequalities
in wealth between the Ethiopian regions, reducing
geographical inequalities in U5MR could also indir-
ectly reduce socioeconomic inequalities [3].
Conclusion
Pneumonia is among the major causes of under-five
mortality in Ethiopia and increasing treatment coverage
effectively reduces the under-five mortality rate in all
eleven regions. This translates to decreased interindivid-
ual inequalities and increased life expectancy at birth.
Despite large regional variations in incremental cost-
effectiveness ratios, our results indicate that pneumonia
treatment remains cost-effective across Ethiopia. How-
ever, scaling up treatment coverage to 90% in all the re-
gions simultaneously would require substantial resources
and, in practice, the scale-up is more likely to happen
gradually. Prioritizing the intervention scale-up in the
regions with the highest baseline U5MRs would reduce
geographical inequalities in life expectancy; however, this
would save fewer lives as compared to the health maxi-
mizing strategy. Of course, several other scale-up strat-
egies are possible. Our results highlight the challenging
trade-off between two common policy aims for health
budgeting in low-income countries with geographical
diversity: heath maximization and inequality reduction.
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